CN117730864A - Long-acting antibacterial material and preparation method and application thereof - Google Patents
Long-acting antibacterial material and preparation method and application thereof Download PDFInfo
- Publication number
- CN117730864A CN117730864A CN202311618157.6A CN202311618157A CN117730864A CN 117730864 A CN117730864 A CN 117730864A CN 202311618157 A CN202311618157 A CN 202311618157A CN 117730864 A CN117730864 A CN 117730864A
- Authority
- CN
- China
- Prior art keywords
- antibacterial
- film
- antibacterial material
- solvent
- pvdf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 131
- 239000000463 material Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000010936 titanium Substances 0.000 claims abstract description 39
- 239000002033 PVDF binder Substances 0.000 claims abstract description 38
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims abstract description 38
- 239000002904 solvent Substances 0.000 claims abstract description 18
- MJEPCYMIBBLUCJ-UHFFFAOYSA-K sodium titanium(4+) phosphate Chemical compound P(=O)([O-])([O-])[O-].[Ti+4].[Na+] MJEPCYMIBBLUCJ-UHFFFAOYSA-K 0.000 claims abstract description 12
- 238000001179 sorption measurement Methods 0.000 claims abstract description 6
- 239000011521 glass Substances 0.000 claims abstract description 5
- 239000002002 slurry Substances 0.000 claims abstract description 5
- 150000002500 ions Chemical class 0.000 claims abstract description 4
- 230000001112 coagulating effect Effects 0.000 claims abstract description 3
- 239000011248 coating agent Substances 0.000 claims abstract description 3
- 238000000576 coating method Methods 0.000 claims abstract description 3
- 239000002245 particle Substances 0.000 claims abstract description 3
- 230000000845 anti-microbial effect Effects 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000008367 deionised water Substances 0.000 claims description 16
- 229910021641 deionized water Inorganic materials 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 12
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical group CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 101710134784 Agnoprotein Proteins 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 230000015271 coagulation Effects 0.000 claims description 4
- 238000005345 coagulation Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- YHWCPXVTRSHPNY-UHFFFAOYSA-N butan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCC[O-].CCCC[O-].CCCC[O-].CCCC[O-] YHWCPXVTRSHPNY-UHFFFAOYSA-N 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000007605 air drying Methods 0.000 claims description 2
- 238000012360 testing method Methods 0.000 abstract description 39
- 241000588724 Escherichia coli Species 0.000 abstract description 20
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 20
- 239000002105 nanoparticle Substances 0.000 abstract description 14
- 230000002045 lasting effect Effects 0.000 abstract description 6
- 239000011149 active material Substances 0.000 abstract description 2
- 239000000945 filler Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 27
- 230000005764 inhibitory process Effects 0.000 description 24
- 239000007788 liquid Substances 0.000 description 24
- 239000011550 stock solution Substances 0.000 description 23
- 230000003287 optical effect Effects 0.000 description 18
- 239000002131 composite material Substances 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 12
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 229910052709 silver Inorganic materials 0.000 description 10
- 239000004332 silver Substances 0.000 description 10
- 238000002791 soaking Methods 0.000 description 10
- -1 silver ions Chemical class 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 235000012431 wafers Nutrition 0.000 description 6
- 206010064687 Device related infection Diseases 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000000399 orthopedic effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 208000011354 prosthesis-related infectious disease Diseases 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 241000589291 Acinetobacter Species 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910010413 TiO 2 Inorganic materials 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000001027 hydrothermal synthesis Methods 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000012621 metal-organic framework Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002070 nanowire Substances 0.000 description 1
- 239000012766 organic filler Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Manufacture Of Macromolecular Shaped Articles (AREA)
Abstract
The invention discloses a long-acting antibacterial material, and a preparation method and application thereof. The antibacterial material takes sodium titanium phosphate as an adsorption carrier, ag ions are adsorbed on the surface of the sodium titanium phosphate, and the average particle size of the antibacterial material is smaller than 200nm. Uniformly dissolving PVDF slurry and an antibacterial material in a first solvent, coating the solution on a glass plate, then entering a coagulating bath, curing to obtain a primary film, and removing the solvent in the primary film to obtain the durable antibacterial Ag-Ti/PVDF film. In the invention, taking common escherichia coli and staphylococcus aureus B as examples, the PVDF film only containing 1wt% of Ag-Ti nanoparticle filler shows excellent lasting antibacterial performance in the tests of a bacteriostasis zone and a bacteriostasis rate. The invention effectively solves the bottleneck of slow release and lasting antibacterial activity of the antibacterial material, and opens up a new way for practical application of the lasting antibacterial active material.
Description
Technical Field
The invention belongs to the field of antibacterial materials, and particularly relates to a long-acting antibacterial material, and a preparation method and application thereof.
Background
In recent years, the number of people who have suffered from serious diseases and sepsis due to bacterial and other microbial infections has increased. To overcome infections caused by bacteria, the use of antibiotics is often a common strategy. However, overuse of antibiotics has led to the development of multi-drug resistant bacteria, and therefore, stronger or more complex antibiotic formulations are needed to effectively combat them. An alternative way to minimize the impact of this problem is to prevent, i.e. to avoid the proliferation of bacteria on different substrate surfaces by blocking their growth and development or simply preventing their adhesion. In this sense, research and development of novel antibacterial materials is becoming a good approach.
Polymers and polymer-based materials have many different applications, for example as a framework in the biomedical field. Among the many desirable functions of medical materials, antibacterial action occupies a primary position because bacterial growth on medical devices, prosthetic materials, catheters (urinary or venous catheters) and surgical masks can be prevented. Polymer-based antimicrobial materials are also very useful in food science and technology. It is desirable to use antimicrobial materials to prepare active or smart packages to improve food quality and extend shelf life.
The use of antimicrobial materials has become indispensable in the biomedical and related scientific technology fields. Many people die each year from pathogen infection. Among the different pathogens (bacteria, viruses, fungi, algae, etc.), the pharmaceutical industry is particularly concerned with bacteria, mainly due to the presence of so-called multi-drug resistant bacteria (MDR). Antibiotic resistance is one of the greatest risks faced by the world health organization (world health organization) in terms of global health and food safety, as antibiotic resistance can affect anyone at any age and anywhere in the world. The most common bacteria are Acinetobacter, pseudomonas and some enterobacteria, such as Klebsiella, E.coli, serratia and Proteus. These bacteria can cause serious infections such as blood infections and pneumonia, and even death.
Bacterial growth on biomedical devices and implant surfaces is believed to be the primary cause of device-related infections (device related infections, DRI). Some studies consider the effects of infection due to bacterial colonization in medical devices, reporting that urinary catheter infection and central venous infection are the most common infections, followed by orthopedic implants. Contamination can lead to colony formation and then to mature biofilms. In addition to catheters, prosthetic heart valves, pacemakers, vascular grafts, orthopedic implants or prosthetic joints, contact lenses, and the like, also present instrument-related infections. Postoperative infections of orthopedic implants are also common. Methicillin-resistant staphylococcus aureus (MRSA) and escherichia coli are the major causative bacteria of medical device-related infections. One of the most common strategies against these bacteria is the use of controlled release drugs or antibiotics. This approach has some significant benefits because it can inhibit biofilm formation, reducing the risk of infection and thus reducing mortality in the patient.
In recent years, efforts have been made to develop polyvinylidene fluoride (PVDF) -based films having excellent antibacterial properties to prevent the accumulation of surface contaminants. Various organic and inorganic fillers have been reported to be added to PVDF membranes to increase their antimicrobial properties, such as Ag nanoparticles, functionalized graphene, moO 3 Nanowire, nano ZnO powder and nano TiO 2 And a metal organic framework. In general, it is desirable that the effective antimicrobial material incorporated into the PVDF film be able to be released slowly, too quickly, too short in antimicrobial expiration date, and too slowly to achieve an antimicrobial effect. Ag nanoparticles are a recognized high-efficiency antimicrobial material with low loading on low surface area nanoparticles. In principle, the amount and release of silver ions adsorbed depends on the surface area of the substrate and the interaction of the silver ions with the substrate. Therefore, the amount of adsorption and controlled release rate of effective antimicrobial ions is a critical issue. How to overcome the problems and provide an efficient and reasonable antibacterial method, which is to be solvedThe technical problem of the block.
Disclosure of Invention
In order to solve the problems in the prior art, the invention aims to overcome the defects existing in the prior art and provide a method for lasting antibacterial activity, wherein the antibacterial film material is prepared by selecting a nanoparticle with electronegativity as a carrier material for loading silver ions and then combining PVDF, and the nanoparticle with strong electronegativity combines silver ions through electrostatic interaction, so that the method has stronger interaction force than simple physical adsorption, increases adsorption quantity, reduces the release speed of silver ions, and is simple in design method and easy to realize industrialization.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
the invention provides a long-acting antibacterial material, which takes sodium titanium phosphate as an adsorption carrier, and adsorbs Ag ions on the surface of the sodium titanium phosphate, wherein the average particle size of the antibacterial material is smaller than 200nm.
The invention also provides a preparation method of the antibacterial material, which comprises the following steps:
NaTi is processed 2 (PO 4 ) 3 And AgNO 3 Dispersing in deionized water according to a molar ratio of 1:2, uniformly mixing, and centrifuging out precipitate to obtain the antibacterial material.
Further, washing the precipitate with ethanol for three times, and vacuum drying at 80 ℃ to obtain the antibacterial material; the NaTi 2 (PO 4 ) 3 The mass fraction of the water dispersed in the deionized water is 0.2-0.25wt%.
Further, the NaTi 2 (PO 4 ) 3 The preparation method comprises the following specific preparation steps:
will CH 3 COONa and H 3 PO 4 Mixing to obtain solution A; mixing titanium butoxide and ethanol to prepare a solution B; mixing A and B, stirring, placing into a reaction kettle, reacting at 160deg.C for 3 hr, centrifuging, washing with ethanol for three times, and vacuum drying at 80deg.C to obtain NaTi 2 (PO 4 ) 3 And (3) powder.
The invention also provides a long-acting antibacterial film material, which is a PVDF film and uniformly dispersed with the antibacterial material.
Further, the antibacterial film material is prepared by a coagulation bath.
The invention also provides a preparation method of the antibacterial film material, which comprises the following steps:
uniformly dissolving PVDF slurry and an antibacterial material in a first solvent, coating the solution on a glass plate, then entering a coagulating bath, curing to obtain a primary film, and removing the solvent in the primary film to obtain the durable antibacterial Ag-Ti/PVDF film.
Further, the first solvent is an N-methylpyrrolidone solvent, and the coagulation bath is deionized water.
Further, the specific method for removing the solvent in the film forming comprises the following steps: air-drying at room temperature for not less than 48 hr or drying at 80deg.C for at least 8 hr.
Compared with the prior art, the invention has the following outstanding substantive features and remarkable advantages:
1. according to the invention, by utilizing the property of a simple negative sol solution, silver nitrate is added into the suspension of the sodium titanium phosphate nano particles, the nano-scale surface area of the nano particles can provide a large number of attachment sites for silver ions, the nano particles can be effectively used as a silver ion carrier, and the electrostatic interaction force between the silver ions and the sodium titanium phosphate nano particles can ensure the slow release of the silver ions so as to achieve an effective lasting antibacterial effect.
2. According to the method, the antibacterial material and PVDF are effectively combined to form the antibacterial film material, so that the antibacterial film material has high antibacterial activity on escherichia coli and staphylococcus aureus, and can keep lasting antibacterial activity.
3. The method solves the bottleneck problems of low silver ion load and incapability of slowly releasing silver ions, has simple preparation process and easy realization, and opens up a new way for preparing the durable antibacterial active material.
Drawings
FIG. 1 shows the preparation of NaTi by the method of example 1 of the present invention 2 (PO 4 ) 3 Is a TEM image of (1).
FIG. 2 shows the preparation of NaTi by the method of example 1 of the present invention 2 (PO 4 ) 3 Is a XRD pattern of (C).
FIG. 3 shows the preparation of AgNO by the method of example 2 of the present invention 3 -NaTi 2 (PO 4 ) 3 TEM image of (Ag-Ti).
FIG. 4 is an XRD pattern for Ag-Ti prepared by the method of example 2 of this invention.
FIG. 5 is an optical image of Ag-Ti/PVDF films of varying Ag-Ti content prepared by the method of example 3 of this invention.
FIG. 6 is an optical image of the results of the zone of inhibition test of Staphylococcus aureus B using different antimicrobial films according to example 3 of the present invention.
FIG. 7 is a measurement result of the diameter of a zone of inhibition obtained in example 3 of the present invention using different antibacterial films to inhibit Staphylococcus aureus B.
FIG. 8 is an optical image of the results of the inhibition test of Staphylococcus aureus B using different antimicrobial films according to example 3 of the present invention.
FIG. 9 is an optical image of the results of the inhibition test of Staphylococcus aureus B using different antimicrobial films according to example 3 of the present invention.
FIG. 10 is an optical image of the results of the inhibition test of Staphylococcus aureus B using different antimicrobial films according to example 3 of the present invention.
FIG. 11 is an optical image of the results of the inhibition test of Staphylococcus aureus B using different antimicrobial films according to example 3 of the present invention.
FIG. 12 is a data statistic of the results of the inhibition test of Staphylococcus aureus B using different antibacterial films according to example 3 of the present invention.
FIG. 13 is an optical image of the results of the inhibition test of Staphylococcus aureus B using different antimicrobial films according to example 3 of the present invention.
FIG. 14 is an optical image of the results of the inhibition test of Staphylococcus aureus B using different antimicrobial films according to example 3 of the present invention.
FIG. 15 is an optical image of the results of the inhibition test of Staphylococcus aureus B using different antimicrobial films according to example 3 of the present invention.
FIG. 16 is a data statistic of the results of the inhibition test of Staphylococcus aureus B using different antibacterial films according to example 3 of the present invention.
FIG. 17 is an optical image of the results of the inhibition zone test of E.coli inhibition using different antimicrobial films according to example 4 of the present invention.
FIG. 18 shows the measurement results of the diameter of the inhibition zone obtained by using different antibacterial films to inhibit E.coli in example 4 of the present invention.
FIG. 19 is an optical image of the results of the antibacterial rate test for E.coli inhibition using different antibacterial films according to example 4 of the present invention.
FIG. 20 is an optical image of the results of the antibacterial rate test for E.coli inhibition using different antibacterial films according to example 4 of the present invention.
FIG. 21 is an optical image of the results of the antibacterial rate test for E.coli inhibition using different antibacterial films according to example 4 of the present invention.
FIG. 22 is an optical image of the results of the inhibition test of E.coli using different antibacterial films according to example 4 of the present invention.
FIG. 23 is a data statistics of the results of the antibacterial rate test of example 4 of the present invention using different antibacterial films to inhibit E.coli.
FIG. 24 is an optical image of the results of the antibacterial rate test for E.coli inhibition using different antibacterial films according to example 4 of the present invention.
FIG. 25 is an optical image of the results of the antibacterial rate test for E.coli inhibition using different antibacterial films according to example 4 of the present invention.
FIG. 26 is an optical image of the results of the antibacterial rate test for E.coli inhibition using different antibacterial films according to example 4 of the present invention.
FIG. 27 is a data statistics of the results of the antibacterial rate test of example 4 of the present invention using different antibacterial films to inhibit E.coli.
Detailed Description
The foregoing aspects are further described in conjunction with specific embodiments, and the following detailed description of preferred embodiments of the present invention is provided:
in the invention, during the test of the inhibition zone, the original solution of the inhibition solution means that bacteria are incubated for 24 hours at 37 ℃, and the concentration after dilution is about 5 multiplied by 10 7 CFU/mL antibacterial solution; during the bacteriostasis rate test, the stock solution of the bacteriostasis liquid is that bacteria are incubated for 24 hours at 37 ℃ and the concentration after dilution is about 1 multiplied by 10 8 CFU/mL antibacterial solution.
In the invention, staphylococcus aureus B is purchased from Tiangen Biochemical technology Co., ltd, and the model is ATCC6538; coli was purchased from Tiangen Biochemical technology Co., ltd, model number ATCC25922.
Example 1: naTi (NaTi) 2 (PO 4 ) 3 Preparation and characterization of (2)
a.NaTi 2 (PO 4 ) 3 Is prepared from the following steps:
by hydrothermal reaction, 0.16g of CH 3 COONa and 6ml 85wt% H 3 PO 4 Mixing to obtain solution A; mixing 0.68g of titanium butoxide and 40mL of ethanol to prepare a solution B; mixing the A and the B, uniformly stirring, placing the mixture into a 100mL reaction kettle for reaction at 160 ℃ for 3 hours, centrifuging, washing with ethanol for three times, and drying in vacuum at 80 ℃ for later use.
b. Characterization of results:
TEM results were tested in an atmospheric environment using a transmission electron microscope (JEOL 2100F model) and are shown in FIG. 1.
XRD diffraction results were shown in FIG. 2, as measured in an atmospheric environment using an X-ray diffractometer (Rigaku D/Max-2200V PC model).
Example 2: preparation and characterization of Ag-Ti composite material
Preparation of Ag-Ti composite material:
NaTi is processed 2 (PO 4 ) 3 And AgNO 3 Dispersing in deionized water according to a molar ratio of 1:2, uniformly mixing, centrifuging out precipitate, washing with ethanol for three times, and vacuum drying at 80 ℃ for later use.
b. Characterization of results:
TEM results were tested in an atmospheric environment using a transmission electron microscope (JEOL 2100F model) and are shown in FIG. 3.
XRD diffraction results were shown in FIG. 4, as measured in an atmospheric environment using an X-ray diffractometer (Rigaku D/Max-2200V PC model).
Example 3: preparation of Ag-Ti/PVDF film and antibacterial test of staphylococcus aureus B
Preparation of Ag-Ti/PVDF film:
PVDF slurry (Mw=1000000) and 0wt%, 1wt%, 3wt% and 5wt% of Ag-Ti composite material are mixed in N-methyl pyrrolidone solvent, then cast on a glass plate, and immersed in deionized water for solvent exchange, thus obtaining the durable antibacterial Ag-Ti/PVDF film without N-methyl pyrrolidone solvent. Finally, drying at 80 ℃ for 8 hours to obtain the antibacterial film material.
b. Staphylococcus aureus B inhibition zone test:
cutting the pure PVDF film prepared in the step a and the Ag-Ti/PVDF film containing 1, 3 and 5wt% of Ag-Ti composite material into a wafer with the diameter of 16 mm for later use; the wafer was tested in an atmospheric environment using a SHOTON MI 6X model instrument, the results of which are shown in FIG. 5.
The concentration of the antibacterial solution used for testing the antibacterial zone is about 5 multiplied by 10 7 CFU/mL is determined as stock solution of antibacterial solution for standby. And d, placing the wafer obtained in the step b into antibacterial liquid for 24 hours, and adopting a SHOTON MI 6X type instrument to test in an atmospheric environment, wherein the result is shown in figure 6.
The diameter of the sterile circle in fig. 6 is measured three times by adopting a scale to average, a comparison table of the diameter of the sterile circle is made, and the statistics of the result are shown in fig. 7.
c. Staphylococcus aureus B bacteriostasis rate test:
cutting the pure PVDF film prepared in the step a and the Ag-Ti/PVDF film material containing 1, 3 and 5wt% of Ag-Ti composite material into fragments with the size of 3 square millimeters for later use;
respectively placing the fragments into a stock solution of the antibacterial liquid, and diluting the stock solution of the antibacterial liquid by 1 x 10 -1 Dilution of stock solution of antibacterial solution 1 x 10 -2 Dilution of stock solution of antibacterial solution 1 x 10 -4 After 24 hours in the antibacterial liquid, the antibacterial liquid is tested in an atmospheric environment by adopting a SHOTON MI 6X type instrument, and the results are respectively shown in fig. 8, 9, 10 and 11. Counting the number of colonies after the test, and obtaining the resultSee fig. 12. Wherein the stock solution of the antibacterial liquid is defined as the concentration of about 1×10 8 CFU/mL antibacterial solution.
d. After deionized water soaking, testing the bacteriostasis rate of staphylococcus aureus B:
c, soaking the Ag-Ti/PVDF film material containing 1wt% of the Ag-Ti composite material prepared in the step a in deionized water for different days, and shearing the material into fragments with the size of 3 square millimeters by using scissors for later use;
respectively placing the fragments into a stock solution of the antibacterial liquid, and diluting the stock solution of the antibacterial liquid by 1 x 10 -1 Dilution of stock solution of antibacterial solution 1 x 10 -2 Dilution of stock solution of antibacterial solution 1 x 10 -4 After 24 hours in the obtained antibacterial liquid, the antibacterial liquid is tested in an atmospheric environment by adopting a SHOTON MI 6X type instrument, the result of soaking in deionized water for 1 day is shown in fig. 13, the result of soaking for 2 days is shown in fig. 14, and the result of soaking for 3 days is shown in fig. 15. The number of colonies was counted after the test, and the results are shown in FIG. 16. Wherein the stock solution of the antibacterial liquid is defined as the concentration of about 1×10 8 CFU/mL antibacterial solution.
Example 4: preparation of Ag-Ti/PVDF film and antibacterial test of escherichia coli
Preparation of Ag-Ti/PVDF film:
step a) was performed as in example 3.
b. And (3) testing a bacteriostasis zone of escherichia coli:
the pure PVDF film prepared in the step a and the Ag-Ti/PVDF film containing 1, 3 and 5wt% of Ag-Ti composite materials are cut into wafers with the diameter of 16 mm for standby.
The concentration of the antibacterial solution used for testing the antibacterial zone is about 5 multiplied by 10 7 CFU/mL is determined as stock solution of antibacterial solution for standby. After the prepared wafer is placed into the antibacterial liquid for 24 hours, the wafer is tested in an atmospheric environment by adopting a SHOTON MI 6X type instrument, and the result is shown in figure 17.
The diameter of the sterile circle in fig. 17 is measured three times by adopting a scale to average, a comparison table of the diameter of the sterile circle is made, and the statistics of the result are shown in fig. 18.
c. And (3) testing the bacteriostasis rate of escherichia coli:
cutting the pure PVDF film prepared in the step a and the Ag-Ti/PVDF film material containing 1, 3 and 5wt% of Ag-Ti composite material into fragments with the size of 3 square millimeters for later use;
respectively placing the fragments into a stock solution of the antibacterial liquid, and diluting the stock solution of the antibacterial liquid by 1 x 10 -1 Dilution of stock solution of antibacterial solution 1 x 10 -2 Dilution of stock solution of antibacterial solution 1 x 10 -4 After 24 hours in the obtained antibacterial liquid, the antibacterial liquid is tested in an atmospheric environment by adopting a SHOTON MI 6X type instrument, and the results are shown in FIG. 19, FIG. 20, FIG. 21 and FIG. 22 respectively. The number of colonies was counted after the test, and the results are shown in FIG. 23. Wherein the stock solution of the antibacterial liquid is defined as the concentration of about 1×10 8 CFU/mL antibacterial solution.
d. After deionized water soaking, the bacteriostasis rate of the escherichia coli is tested:
c, soaking the Ag-Ti/PVDF film material containing 1wt% of the Ag-Ti composite material prepared in the step a in deionized water for different days, and shearing the material into fragments with the size of 3 square millimeters by using scissors for later use;
respectively placing the fragments into a stock solution of the antibacterial liquid, and diluting the stock solution of the antibacterial liquid by 1 x 10 -1 Dilution of stock solution of antibacterial solution 1 x 10 -2 Dilution of stock solution of antibacterial solution 1 x 10 -4 After 24 hours in the obtained antibacterial liquid, the antibacterial liquid is tested in an atmospheric environment by adopting a SHOTON MI 6X type instrument, the result of soaking in deionized water for 1 day is shown in FIG. 24, the result of soaking for 2 days is shown in FIG. 25, and the result of soaking for 3 days is shown in FIG. 26. The number of colonies was counted after the test, and the results are shown in FIG. 27. Wherein the stock solution of the antibacterial liquid is defined as the concentration of about 1×10 8 CFU/mL antibacterial solution.
In view of the above examples, referring to fig. 1 to 27, it can be clearly seen from fig. 1 that the prepared sodium titanium phosphate nanoparticles have uniform size and complete morphology, and that the crystalline phases of the synthesized sodium titanium phosphate nanoparticles correspond to standard peaks, which proves the successful synthesis of the sodium titanium phosphate nanoparticles. Fig. 3 shows a transmission electron microscope image of the synthesized ag—ti composite material, and it can be seen that silver is adsorbed on the nanoparticles, and the comparison between the peak positions of the sodium titanium phosphate by XRD test is made (fig. 4). Fig. 5 shows an optical image of the prepared Ag-Ti/PVDF film material, with a flat film surface, without significant voids and fluctuations. After the Ag-Ti composite materials with different mass fractions are added, the surface is not obviously changed, and the aggregation of the Ag-Ti composite materials is not found, so that the dispersion is good. Fig. 6-12 show the antibacterial effect of the antibacterial film on staphylococcus aureus B, and the antibacterial effect of the antibacterial film on the antibacterial zone and the antibacterial rate under different concentrations of antibacterial liquid are compared, so that it can be obviously seen that the 1wt% ag-Ti composite material has reached a certain antibacterial effect. FIGS. 13-16 show the antibacterial effect test of antibacterial films containing 1wt% Ag-Ti composite materials respectively immersed in deionized water for different days, and the antibacterial effect is maintained at a certain level. Similarly, FIGS. 17-27 are graphs showing that an antibacterial effect against E.coli was achieved by an antibacterial film of 1wt% Ag-Ti composite material. The above examples illustrate that a 1wt% Ag-Ti/PVDF film can achieve effective antimicrobial efficacy, opening up a new way for practical applications of durable antimicrobial activity.
Example 5: preparation of Ag-Ti/PVDF film
Preparation of Ag-Ti/PVDF film:
PVDF slurry (Mw=1000000) and 0wt%, 1wt%, 3wt% and 5wt% of Ag-Ti composite material are mixed in N-methyl pyrrolidone solvent, then cast on a glass plate, and immersed in deionized water for solvent exchange, thus obtaining the durable antibacterial Ag-Ti/PVDF film without N-methyl pyrrolidone solvent. Finally, airing at room temperature for at least 48 hours to obtain the antibacterial film material.
The embodiments of the present invention have been described above with reference to the accompanying drawings, but the present invention is not limited to the embodiments described above, and various changes, modifications, substitutions, combinations or simplifications can be made according to the purposes of the present invention, which are the spirit and principles of the technical solution of the present invention, and the present invention is not limited to the technical principles and the inventive concepts of the method for durable antimicrobial activity of the present invention, as long as the present invention is satisfied.
Claims (9)
1. The long-acting antibacterial material is characterized in that the antibacterial material takes sodium titanium phosphate as an adsorption carrier, ag ions are adsorbed on the surface of the sodium titanium phosphate, and the average particle size of the antibacterial material is smaller than 200nm.
2. The method for preparing the antibacterial material according to claim 1, which comprises the following steps:
NaTi is processed 2 (PO 4 ) 3 And AgNO 3 Dispersing in deionized water according to a molar ratio of 1:2, uniformly mixing, and centrifuging out precipitate to obtain the antibacterial material.
3. The preparation method of claim 2, wherein the precipitate is washed three times with ethanol and dried in vacuum at 80 ℃ to obtain the antibacterial material; the NaTi 2 (PO 4 ) 3 The mass fraction of the water dispersed in the deionized water is 0.2-0.25wt%.
4. The method of claim 2, wherein the niti 2 (PO 4 ) 3 The preparation method comprises the following specific preparation steps:
will CH 3 COONa and H 3 PO 4 Mixing to obtain solution A; mixing titanium butoxide and ethanol to prepare a solution B; mixing A and B, stirring, placing into a reaction kettle, reacting at 160deg.C for 3 hr, centrifuging, washing with ethanol for three times, and vacuum drying at 80deg.C to obtain NaTi 2 (PO 4 ) 3 And (3) powder.
5. A long-acting antibacterial film material, wherein the antibacterial film material is a PVDF film, and the antibacterial material according to claim 1 is uniformly dispersed.
6. The antimicrobial film material of claim 5, wherein the antimicrobial film material is prepared by a coagulation bath.
7. The method for preparing the antibacterial film material as claimed in claim 6, which is characterized by comprising the following steps:
uniformly dissolving PVDF slurry and an antibacterial material in a first solvent, coating the solution on a glass plate, then entering a coagulating bath, curing to obtain a primary film, and removing the solvent in the primary film to obtain the durable antibacterial Ag-Ti/PVDF film.
8. The method of claim 7, wherein the first solvent is an N-methylpyrrolidone solvent and the coagulation bath is deionized water.
9. The method according to claim 7, wherein the specific method for removing the solvent in the primary film comprises: air-drying at room temperature for not less than 48 hr or drying at 80deg.C for at least 8 hr.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311618157.6A CN117730864A (en) | 2023-11-30 | 2023-11-30 | Long-acting antibacterial material and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311618157.6A CN117730864A (en) | 2023-11-30 | 2023-11-30 | Long-acting antibacterial material and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117730864A true CN117730864A (en) | 2024-03-22 |
Family
ID=90278532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311618157.6A Pending CN117730864A (en) | 2023-11-30 | 2023-11-30 | Long-acting antibacterial material and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117730864A (en) |
-
2023
- 2023-11-30 CN CN202311618157.6A patent/CN117730864A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Adepu et al. | Broad-spectrum antimicrobial activity of bacterial cellulose silver nanocomposites with sustained release | |
| US9869037B2 (en) | Method of producing a swellable polymer fibre | |
| Singh et al. | Chitin membranes containing silver nanoparticles for wound dressing application | |
| US20100068296A1 (en) | Methods for producing an anti-microbial plastic product | |
| US9192625B1 (en) | Antimicrobial nanocomposite compositions, fibers and films | |
| JP2012533568A (en) | Particles containing antibacterial substances | |
| CN107254742B (en) | The composite fiber web of polyvinyl alcohol/sericin containing nano silver for medical dressing | |
| Lei et al. | Fabrication of a novel antibacterial TPU nanofiber membrane containing Cu-loaded zeolite and its antibacterial activity toward Escherichia coli | |
| Jiang et al. | Fabrication of silver nanowires-loaded polydimethylsiloxane film with antimicrobial activities and cell compatibility | |
| CA2761866A1 (en) | Nanostructural composition of biocide | |
| Yang et al. | The synthesis of nano-silver/sodium alginate composites and their antibacterial properties | |
| Rădulescu et al. | Antimicrobial coatings based on zinc oxide and orange oil for improved bioactive wound dressings and other applications | |
| CN107096069B (en) | Core-shell structure nano composite material of silver nano particles coated with hydroxyapatite and preparation method thereof | |
| CN101791433B (en) | Molecular sieve antibacterial coating with pure titanium or titanium alloy surface and preparation method thereof | |
| US9723843B2 (en) | Family of silver (I) periodate compounds having broad microbial properties | |
| Srivastava et al. | Potential of electrospun cellulose acetate nanofiber mat integrated with silver nanoparticles from Azadirachta indica as antimicrobial agent | |
| CN100390351C (en) | Antibacterial active carbon fiber coated by chitosan porous membrane and process for preparing same | |
| CN108300897B (en) | Low-modulus silver-containing anti-infection medical titanium alloy | |
| CN112972769B (en) | Method for preparing nano-silver-containing antibacterial peptide functional coating on metal surface | |
| CN117730864A (en) | Long-acting antibacterial material and preparation method and application thereof | |
| Xue et al. | A highly efficient, low-toxic, wide-spectrum antibacterial coating designed for 3D printed implants with tailorable release properties | |
| CN114504675B (en) | Ag NPS @ oxidized tea polyphenol-acrylic hydrogel and preparation and application thereof | |
| US20110091557A1 (en) | Composite material | |
| CN116570766A (en) | Ag-TiO 2 Preparation method of OTS hydrophobic coating and application of OTS hydrophobic coating as antibacterial implant | |
| Deshmukh et al. | Low-temperature-processed biocompatible Ag-HAp nanoparticles with anti-biofilm efficacy for tissue engineering applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |